Preprint Review Version 1 This version is not peer-reviewed

Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin’s Lymphoma: Case Report and Review of the Literature

Version 1 : Received: 14 August 2024 / Approved: 14 August 2024 / Online: 14 August 2024 (13:59:29 CEST)

How to cite: Banegas, D. E.; Moioli, A.; Santoni, E.; Tagliavini, E.; Quaglia, F. M.; Bernardelli, A.; Visco, C. Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin’s Lymphoma: Case Report and Review of the Literature. Preprints 2024, 2024081069. https://doi.org/10.20944/preprints202408.1069.v1 Banegas, D. E.; Moioli, A.; Santoni, E.; Tagliavini, E.; Quaglia, F. M.; Bernardelli, A.; Visco, C. Visceral Leishmaniasis Following A+AVD Treatment in a Patient with Classical Hodgkin’s Lymphoma: Case Report and Review of the Literature. Preprints 2024, 2024081069. https://doi.org/10.20944/preprints202408.1069.v1

Abstract

We report the case of a 45-year-old Caucasian man who was treated upfront with brentuximab vedotin (A) and doxorubicin, vinblastine, and dacarbazine (AVD; A+AVD) for advanced-stage classical Hodgkin's lymphoma (cHL). Right after completing the 6th cycle of induction therapy, he developed serotine fever, progressive clinical deterioration, symptomatic splenomegaly and se-vere anemia. Extensive infectious disease evaluations and serial PET scans were conducted to rule out lymphoma progression. Finally, a diagnosis of visceral leishmaniasis (VL) was performed. The patient was treated with parenteral amphotericin B, with rapid and complete resolution of clinical and laboratory abnormalities. We described this rare case of infectious complication after A+AVD delivered for cHL, and we performed a comprehensive review of the literature on the occurrence of VL in the context of non-HL and cHL, since this infection is becoming increasingly prevalent in non-tropical countries.

Keywords

Hodgkin’s Lymphoma; Brentuximab-AVD; (A+AVD); Visceral leishmaniasis; splenomegaly

Subject

Medicine and Pharmacology, Hematology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.